Welcome to our dedicated page for SOLENO THERAPEUTICS SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soleno Therapeutics filings document the regulatory, financial, governance, and capital-structure disclosures of a Nasdaq-listed biopharmaceutical company commercializing VYKAT XR for hyperphagia associated with Prader-Willi syndrome. Recent Form 8-K reports cover operating results and launch updates, regulatory and marketing-authorization matters for diazoxide choline, material agreements, share-repurchase arrangements, and the company's common stock registration on Nasdaq.
The filing record also includes board-approved bylaw amendments, officer appointments and compensation arrangements, exhibits to earnings releases, and material-event disclosures related to strategic transactions. These documents formalize the company's public reporting around product commercialization, corporate governance, executive compensation, and risk-related business developments.
Soleno Therapeutics officer Patricia C. Hirano reported new equity awards. On January 21, 2026, she received 10,400 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share. These RSUs are scheduled to vest 100% on December 15, 2027, if she continues as a service provider under the company’s equity plan through that date.
On the same day, she was also granted an employee stock option for 11,900 shares of Common Stock at an exercise price of $43.65 per share. One forty-eighth of these option shares start vesting on February 1, 2026 and then monthly thereafter, contingent on continued service, and the option expires on January 21, 2036. After these transactions, she beneficially owned 22,702 shares of Common Stock directly, along with the newly granted option.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 114,200 shares of Common Stock at $0 cost, identified in the footnotes as restricted stock units (RSUs) that each represent a right to one share of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.
On the same date, Bhatnagar was granted an employee stock option covering 131,400 shares of Common Stock at an exercise price of $43.65 per share. The option begins vesting on February 1, 2026, with 1/48th of the shares vesting on that date and on each monthly anniversary thereafter, subject to continued service. After these transactions, he directly held 583,656 shares of Common Stock and 131,400 derivative securities (stock options).
Soleno Therapeutics, Inc. updated compensation for its top executives and adopted a new change in control and severance plan. For 2026, the Board approved higher base salaries and 2025 cash bonuses for the named officers, including a $765,000 salary and $487,740 bonus for CEO Anish Bhatnagar, along with stock options and restricted stock awards for each executive.
The new Key Executive Change in Control and Severance Plan covers all Vice Presidents and above, including the named officers. If an executive is terminated without cause or resigns for good reason outside a change in control period, the CEO can receive 18 months of salary, a 100% target bonus and 18 months of COBRA coverage, with 25% equity vesting acceleration, while other senior executives receive shorter salary and COBRA periods without equity acceleration. If such a termination occurs during the change in control period, the CEO can receive 24 months of salary, a 150% target bonus, 24 months of COBRA coverage and full equity acceleration, with similarly enhanced benefits and full equity vesting for other covered executives.
Soleno Therapeutics, Inc. filed a Form 8-K to report that it issued a press release announcing certain preliminary financial results and operating metrics for the three months and year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The information is furnished under the results of operations and financial condition disclosure items and is explicitly stated as "furnished" rather than "filed," which limits how it is treated under securities law and in other future SEC filings.
Soleno Therapeutics insider reports routine tax withholding transaction. A senior officer of Soleno Therapeutics Inc. reported an automatic disposition of company stock related to vested restricted stock units on December 15, 2025.
The filing shows that 904 shares of common stock were withheld by the company at a price of $49.95 per share to cover the officer's tax obligations when RSUs vested. After this transaction, the officer beneficially owned 27,239 shares of Soleno Therapeutics common stock. The reported RSUs each represent a contingent right to receive one share of common stock, subject to vesting conditions.
The reporting person serves as SVP Global Clinical Operations and Patient Advocacy, and this filing reflects a standard administrative equity compensation event rather than an open-market trade.
Soleno Therapeutics insider updates equity holdings after RSU vesting
A Soleno Therapeutics officer, the Chief Commercial Officer, reported an automatic share withholding related to restricted stock units. On December 15, 2025, the company withheld 1,922 shares of common stock at $49.95 per share to cover the reporting person's tax obligations when RSUs vested on that date. After this tax withholding, the officer beneficially owned 43,429 shares of common stock, some of which are RSUs, with each RSU representing a contingent right to receive one share subject to its vesting schedule and conditions.
Soleno Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, James Mackaness. On December 15, 2025, 2,013 shares of common stock were disposed of at a price of $49.95 per share. The shares were withheld by the company to cover the officer’s tax obligations arising from the vesting and settlement of restricted stock units (RSUs).
Following this tax withholding transaction, the reporting person beneficially owns 103,163 shares of Soleno Therapeutics common stock. A portion of this balance consists of RSUs, each representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.
Soleno Therapeutics senior vice president of clinical development reported a routine share withholding transaction related to equity compensation. On December 15, 2025, the officer had 812 shares of common stock withheld by the company at a price of $49.95 per share to cover tax obligations arising from the vesting and settlement of restricted stock units (RSUs). After this tax withholding, the officer beneficially owned 36,005 shares of Soleno Therapeutics common stock. Some of these holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to vesting schedules and conditions.
Soleno Therapeutics officer and Senior Vice President of Regulatory Affairs reported an automatic share withholding related to vested restricted stock units (RSUs). On December 15, 2025, 904 shares of common stock were withheld by the company to cover the reporting person’s tax obligations upon RSU settlement at a price of $49.95 per share. After this tax withholding transaction, the insider beneficially owned 12,302 shares of Soleno Therapeutics common stock. Certain of the remaining holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to their vesting schedules and conditions.
Soleno Therapeutics chief executive officer and director Anish Bhatnagar reported equity transactions in company stock. On December 15, 2025, 7,620 shares of common stock were withheld by the company at a price of $49.95 to cover tax obligations related to vested restricted stock units. On the same date, he transferred 100,000 shares of common stock as a gift, for no consideration, to two family trusts for the benefit of his descendants.
After these transactions, Bhatnagar beneficially owned 469,456 shares of Soleno Therapeutics common stock, some of which are in the form of restricted stock units, each representing a contingent right to receive one share subject to vesting conditions. He reports beneficial ownership of the gifted shares only to the extent of any pecuniary interest and disclaims beneficial ownership of the shares held by the trusts.